[1]Wei GX, Wang SL, Zhang L, et al. Impact of postoperative pituitary tumor adrenal insufficiency and hormone replacement therapy (HRT) on tumor recurrence[J]. Eur Rev Med Pharmacol Sci, 2017:2671-2675.
[2]Liu J, Zhang C, Hu W, et al. Tumor suppressor p53 and its mutants in cancer metabolism[J]. Can Lett, 2015, 356(2):197-203.
[3]MerinoRamos T, VzquezCalvo , Casas J, et al. Modification of the host cell lipid metabolism induced by hypolipidemic drugs targeting the acetyl coenzyme a carboxylase impairs west Nile virus replication[J]. Antimicrob Agents Chemother, 2015, 60(1):307-315.
[4]李婷, 胡夕春. 非诺贝特抗肿瘤作用的研究进展[J]. 中华乳腺病杂志:电子版, 2013, 7(5):40-44.
[5]Savic LJ, Chapiro J, Duwe G, et al. Targeting glucose metabolism in cancer: new class of agents for locoregional and systemic therapy of liver cancer and beyond [J] ? Hepat Oncol, 2016, 3(1):19-28.
[6]Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond[J]. Cell, 2008, 134(5):703-707.
[7]Wei H, Guo L, Li L, et al. Mechanism of Warburg effect and its effect on tumor metastasis[J]. Chin J Lung Cancer, 2015, 18(3):179-183.
[8]Gordon N, Skinner AM, Pommier RF, et al. Gene expression signatures of breast cancer stem and progenitor cells do not exhibit features of Warburg metabolism[J]. Stem Cell Res Ther, 2015, 6(1):157-162.
[9]Sugiyama Y, Hagiya Y, Nakajima M, et al. The heme precursor 5aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspasedependent apoptosis[J]. Oncol Rep, 2014, 31(3):1282-1286.
[10]Xu Q, Zhang Q, Ishida Y, et al. EGF induces epithelialmesenchymal transition and cancer stemlike cell properties in human oral cancer cells via promoting Warburg effect[J]. Oncotarget, 2016, 8(6):9557-9571.
[11]Hardie DG, Alessi DR. LKB1 and AMPK and the cancermetabolism link ten years after[J]. BMC Biology, 2013, 11(1):36.
[12]Tanaka T, Ikegami Y, Nakazawa H, et al. Lowdose farnesyltransferase inhibitor suppresses HIF1α and snail expression in triplenegative breast cancer MDAMB231 cells in vitro[J]. J Cell Physiol, 2016, 232(1):192-201.
[13]冯建飞, 穆瑞斌. 他汀类调脂药物联合普罗布考降低血脂的疗效观察[J]. 临床医学研究与实践, 2017, 2(24):37-38.
[14]李燕妮, 仲健, 郭秋野,等. 糖尿病肾病患者接受普罗布考联合奥美沙坦酯治疗后糖脂代谢、氧化和炎症反应程度的评估[J]. 海南医学院学报, 2016, 22(22):2699-2702.
[15]Chen ZP, Liu JH, Jiang DY, et al. Clinical observation of blood sugar uncontrolled nonproliferative diabetic retinopathy patients treated by probucol[J]. Chin J Arterioscl, 2011, 19(9):751-755. |